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Abstract
Background: Allogeneic red blood cell transfusion is frequently used in total hip replacement
surgery (THR). However, data on the prognosis of transfused patients are sparse. In this study we
compared the risk of complications following THR in transfused and non-transfused patients.
Methods: A population-based follow-up study was performed using data from medical databases
in Denmark. We identified 28,087 primary THR procedures performed from 1999 to 2007, from
which we computed a propensity score for red blood cell transfusion based on detailed data on
patient-, procedure-, and hospital-related characteristics. We were able to match 2,254 transfused
with 2,254 non-transfused THR patients using the propensity score.
Results: Of the 28,087 THR patients, 9,063 (32.3%) received at least one red blood cell transfusion
within 8 days of surgery. Transfused patients had higher 90-day mortality compared with matched
non-transfused patients: the adjusted OR was 2.2 (95% confidence interval (CI): 1.2-3.8). Blood
transfusion was also associated with increased odds of pneumonia (OR 2.1; CI: 1.2-3.8), whereas
the associations with cardiovascular or cerebrovascular events (OR 1.4; CI: 0.9-2.2) and venous
thromboembolism (OR 1.2; CI: 0.7-2.1) did not reach statistical significance. The adjusted OR of
reoperation due to infection was 0.6 (CI: 0.1-2.9).
Conclusions: Red blood cell transfusion was associated with an adverse prognosis following
primary THR, in particular with increased odds of death and pneumonia. Although the odds
estimates may partly reflect unmeasured bias due to blood loss, they indicate the need for careful
assessment of the risk versus benefit of transfusion even in relation to routine THR procedures.
Background
Primary total hip replacement (THR) is a common surgi-
cal procedure in developed countries, and incidence rates
appear to be increasing [1-3]. Although THR surgery is an
elective procedure (i.e. there is usually time to haemody-
namically stabilize the patient preoperatively), it is associ-
ated with blood loss resulting in transfusion rates between
30-80% [4,5]. Considerable evidence points to an
increase in the risk of serious complications and death in
critically ill patients who are transfused, especially in
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ever, data is limited on the safety of blood transfusion
among orthopaedic patients, including patients undergo-
ing THR, which are considered to be healthier patients
than persons from the general population. Most [10-14]
but not all [15] previous studies on orthopaedic patients
have reported an increased risk of postoperative infections
including pneumonia, short-term mortality, length of
hospital stay, intensive care unit stay, and systemic
inflammatory response syndrome in patients receiving
blood transfusion(s). Interpretation of published findings
is limited by various methodological shortcomings, such
as selected and heterogeneous study populations (e.g. sin-
gle-institution, only patients over 60 years of age, or a
mixture of hip and knee replacement, trauma and hip
fracture patients), retrospective data collection, incom-
plete follow-up, insufficient confounder control, and
small sample sizes.
The objective of this large population-based follow-up
study was to determine whether allogeneic red blood cell
transfusion was associated with increased odds of compli-
cations following THR. Complications recorded included
hospitalization with cardiovascular and/or cerebrovascu-
lar events, venous thromboembolism, pneumonia, reop-
eration due to infection of primary THR, and mortality
within 90 days of primary THR.
Methods
Study population and settings
The National Board of Health and The Danish Data Pro-
tection Agency approved the study. The present study was
conducted among patients undergoing primary THR at
hospitals in the Danish counties of North Jutland, Aarhus,
Funen, and Copenhagen, encompassing 20 orthopaedic
departments. These 20 departments serve approximately
45% of the Danish population (nearly 2.3 million peo-
ple).
Patients were identified via the Danish Hip Arthroplasty
Registry (DHR), a registry of all primary total hip replace-
ments and revisions performed in Denmark since 1995.
Since its establishment, the DHR has recorded 94% of all
procedures performed at 45 orthopaedic departments
[16]. The recorded data, including preoperative, perioper-
ative, and postoperative data, were collected prospectively
by the operating surgeon using standardized forms.
We first identified primary THR procedures registered in
the DHR and performed at the hospitals reporting to the
Danish Transfusion Database from 1 January 1999 to 31
December 2007 (n = 28,709). Patients without possibility
for follow up (n = 90) and bilateral primary THR proce-
dures performed during the same surgery (n = 532 corre-
sponding to 266 patients) were excluded. However, we
did not exclude patients who sustained right and left THR
during the study period as long as surgery was not per-
formed on the same day; those patients were treated as
independent observations. In total, data for 28,087 pri-
mary THR procedures were available for further analyses.
The Danish National Health Service provides tax-sup-
ported healthcare for the entire population, guaranteeing
free access to family physicians and public hospitals.
Unambiguous linkage between various registers can be
performed by means of the civil registration number, a
unique permanent personal identification number given
to all Danish citizens.
Data on allogeneic red blood cell transfusions
The Danish Transfusion Database is a national clinical
registry monitoring the use of blood components. The
database retains data on all blood transfusions adminis-
tered at the included hospitals during the study period
and includes information on the civil registration number
of the patient receiving the specific blood component,
types and number of blood components administered to
the patient, date of delivery of the blood component from
the blood bank, and clinical biochemical data. Via the
Transfusion Database, data was obtained on all allogeneic
transfusions of red blood cells administered to included
patients within eight days of primary THR surgery.
Patients were classified as having received either none or
one or more units. Haemoglobin concentrations meas-
ured preoperatively and at the time of discharge, were also
obtained from the Transfusion Database.
Data on patient outcomes
The five following transfusion-related complications were
defined as outcomes if they occurred within 90 days of the
primary THR procedure: 1) death, 2) hospitalization with
cardiovascular events including myocardial infarction,
congestive heart failure, peripheral vascular disease, or
cerebrovascular events, 3) hospitalization with venous
thromboembolism, including deep venous thrombosis
and/or pulmonary embolism, 4) hospitalization with
pneumonia, and 5) reoperation due to infection. Data on
death were obtained from the Civil Registration System
which has kept daily updated electronic records on any
change of address, date of emigration, and date of death
for the entire Danish population since 1968 [17]. Data on
hospitalizations were identified in the Danish National
Registry of Patients, which has kept information on the
dates of all admissions and discharges including up to 20
diagnoses for every discharge from non-psychiatric hospi-
tals in Denmark since 1977. Diagnoses are classified
according to the Danish version of the International Clas-
sification of Diseases (ICD). The eighth edition (ICD-8)
was used from 1977 to 1993 and the tenth edition (ICD-
10) has been used hereafter. The physician who dis-Page 2 of 12
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on reoperations due to infection were obtained from the
DHR.
Statistics
Propensity score matching
In order to overcome bias due to confounding, we
matched patients receiving red blood cell transfusion to
patients not receiving transfusion with a 1:1 ratio using
propensity score matching [18,19]. Thus, we identified a
set of transfused and non-transfused THR patients who
had a similar baseline chance of being transfused. For this
purpose we computed a propensity score for each patient
using logistic regression. The propensity score reflected
the probability of receiving a red cell transfusion given the
individual patient's covariate values. Covariates (n = 69)
included into the propensity score have been chosen
because they are supposed to be used by physicians in the
decision making regarding the use of red blood cell trans-
fusion or not, according to current transfusion guidelines,
previous literature, and univariate analyses in our study.
Diagnosis for primary THR was categorised as primary
arthrosis, sequelae after trauma (i.e. fresh fracture and late
sequelae from proximal femur fracture, fracture of acetab-
ulum, and traumatic hip dislocation), and other diseases.
Using the Danish National Registry of Patients, we
extracted data on the 18 major comorbidities before pri-
mary THR for each patient, which are generally used for
the construction of the Charlson comorbidity index score
translated from corresponding ICD-8 and ICD-10 hospi-
tal discharge codes [20].
Then, using a macro (available at: http://www2.sas.com/
proceedings/sugi26/p214-26.pdf), we matched each case
(THR patients who received transfusion) to a unique con-
trol (THR patients who did not receive transfusion) on the
propensity score alone. Thus, we started with a 5-digit
match, and if this could not be done, we then continued
to a 4-, 3-, 2-, or 1-digit match. For data regarding the
quality of matches see Additional file 1. Unmatched trans-
fused patients were excluded. We were able to match 2254
transfused THR patients to 2254 unique non-transfused
THR patients.
We evaluated the balance of the covariates between the
two treatment groups before and after matching using
standardized mean differences. A standardized mean dif-
ference that exceeds 0.1 is indicative of significant imbal-
ance between groups.
Information on blood loss during the surgery, which is an
important predictor for transfusion, was not available in
our dataset. Information on smoking status, obesity/
body-mass index (BMI), prior history of transfusion, pre-
operative history of increased perioperative bleeding, and
pre-operative history of chronic anaemia was also not
available and thus not included in the propensity match-
ing score.
Analyses
The study population was followed from the day of pri-
mary THR to the occurrence of death, hospitalization for
cardiovascular or cerebrovascular events, venous throm-
boembolism, pneumonia, reoperation due to infection,
or 90 days after surgery. We used multivariate logistic
regression analysis to assess the association between trans-
fusion and later outcome by computing odds ratios (OR)
and 95% confidence interval (CI) as a measure of relative
risk. We also adjusted for the haemoglobin concentration
1-7 days postoperative as a surrogate measure of blood
loss.
Subgroup analyses were done according to history of pre-
vious hospitalization with cardiovascular events (i.e.
myocardial infarction, congestive heart failure, cerebrov-
ascular, and peripheral vascular disease) and postopera-
tive haemoglobin level (below or above 105 g/l within 7
days of surgery). Because of the relatively small number of
events for each outcome, we used a composite risk esti-
mate combining all five outcomes in the subgroup analy-
ses.
Finally, we performed dose-response analyses on the asso-
ciation between number of transfusions and the compos-
ite outcome.
All statistical analyses were performed using SAS software
(Version 9.1.3; SAS Institute Inc, Cary, NC).
Results
Of the 28,087 THR procedures, 9,063 (32.3%) received ≥
1 red cell transfusion during or within 8 days of primary
THR procedure. The median number of red cell units per
patient transfused was 2 (range: 1 to 20).
Compared with non-transfused patients, transfused
patients were older and had more comorbid conditions
(table 1). Transfused patients were also more likely to be
female, to receive a cemented prosthesis, and to have a
THR procedure of more than two hours. Thus, there were
substantial differences in the patient characteristics
between transfused and non-transfused patients (table 1).
Analyses of the propensity-matched population
Covariates included into the propensity score are pre-
sented in table 2. Using the propensity score matching
method (see Additional file 2), we identified a population
of transfused and non-transfused patients with no sub-
stantial differences for any of the characteristics related to
the risk of transfusion (table 2). The patients who werePage 3 of 12
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BMC Musculoskeletal Disorders 2009, 10:167 http://www.biomedcentral.com/1471-2474/10/167Table 1: Descriptive characteristics of all total hip replacement (THR) patients according to red blood cell transfusion within 8 days of 
surgery.
Transfusion
n = 9,063
No transfusion
n = 19,024
Standardized mean difference***
Age (years)
10-49 338 (3.7%) 1363 (7.2%) 0.18797
50-59 834 (9.2%) 3162 (16.6%) 0.22038
60-69 2098 (23.2%) 6334 (33.3%) 0.18585
70-79 3189 (35.2%) 5957 (31.3%) 0.11451
+80 2604 (28.7%) 2208 (11.6%) 0.42107
Sex
Female 6440 (71.1%) 10450 (54.9%) 0.36876
Primary hip diagnosis
Primary arthrosis 5646 (62.3%) 15588 (81.9%) 0.40642
Trauma 2546 (28.1%) 1628 (8.6%) 0.48898
Other 871 (9.6%) 1808 (9.5%) 0.02348
Comorbidity history (yes)
Myocardial infarction 491 (5.4%) 717 (3.8%) 0.07073
Congestive heart failure 612 (6.8%) 600 (3.2%) 0.17886
Peripheral vascular disease 442 (4.9%) 645 (3.4%) 0.05825
Cerebrovascular disease 990 (10.9%) 1010 (5.3%) 0.22239
Dementia 165 (1.8%) 106 (0.6%) 0.11135
Chronic pulmonary disease 815 (9.0%) 1227 (6.5%) 0.09349
Connective tissue disease 679 (7.5%) 972 (5.1%) 0.11434
Peptic ulcer disease 654 (7.2%) 745 (3.9%) 0.15010
Mild liver disease 167 (1.8%) 214 (1.1%) 0.05590
Diabetes (type I and II) 544 (6.0%) 764 (4.0%) 0.08144
Hemiplegia 19 (0.2%) 19 (0.1%) 0.01715
Moderate to severe renal disease 236 (2.6%) 229 (1.2%) 0.13977
Diabetes with end organ damage 274 (3.0%) 326 (1.7%) 0.10146
Any tumor 1151 (12.7%) 1637 (8.6%) 0.16577Page 4 of 12
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Leukemia 36 (0.4%) 35 (0.2%) 0.05114
Lymphoma 69 (0.8%) 76 (0.4%) 0.06085
Moderate to severe liver disease 63 (0.7%) 39 (0.2%) 0.07666
Metastatic solid tumor 141 (1.6%) 121 (0.6%) 0.11523
Fixation technique
Cemented 4060 (44.8%) 6170 (32.4%) 0.26193
Cementless 2118 (23.4%) 7486 (39.4%) 0.37578
Hybrid 2885 (31.8%) 5368 (28.2%) 0.09093
Type of anesthesia
Regional 5929 (65.4%) 14622 (76.9%) 0.29165
Universal and Combined 3134 (34.6%) 4402 (23.1%) 0.29165
Duration of surgery (minutes)
0-60 1819 (20.1%) 7439 (39.1%) 0.34220
61-120 6199 (68.4%) 11097 (58.3%) 0.10558
>121 1045 (11.5%) 488 (2.6%) 0.34021
20 hospitals performing the THR procedures*
Prophylaxis for heterotopic bone formations **
Yes 600 (6.6%) 1317 (6.9%) 0.01945
No 8463 (93.4%) 17707 (93.1%) 0.02058
Year of surgery
1999 114 (1.3%) 115 (0.6% 0.10403
2000 731 (8.1%) 764 (4.0%) 0.11245
2001 623 (6.9%) 1353 (7.1%) 0.05878
2002 1123 (12.4%) 1757 (9.2%) 0.19310
2003 989 (10.9%) 1669 (8.8% 0.13441
2004 1103 (12.2%) 2570 (13.5%) 0.01450
2005 1410 (15.6%) 3148 (16.6%) 0.08021
2006 1579 (17.4%) 3820 (20.1%) 0.19120
2007 1390 (15.4%) 3828 (20.1%) 0.12261
Data are shown in number (%) unless otherwise specified. * Each of the 20 hospitals performing the THR procedures was treated as separate covariate. 
** Anti -rheumatic drugs were used as prophylaxis for heterotopic bone formation. *** A standardized mean difference that exceeds 0.1 is indicative of 
significant imbalance between groups.
Table 1: Descriptive characteristics of all total hip replacement (THR) patients according to red blood cell transfusion within 8 days of 
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transfusion within 8 days of surgery.
Transfusion n = 2,254 No transfusion n = 2,254 Standardized mean difference***
Age (years)
10-49 146 (6.5%) 159 (7.1%) 0.07561
50-59 272 (12.1%) 256 (11.4%) 0.03827
60-69 602 (26.7%) 635 (28.2%) 0.07124
70-79 830 (36.8%) 793 (35.2%) 0.00596
+80 404 (17.9%) 411 (18.2%) 0.18397
Sex
Female 1,490 (66.1%) 1,439 (63.8%) 0.11293
Primary hip diagnosis
Primary arthrosis 1,647 (73.1%) 1,633 (72.5%) 0.23293
Trauma 323 (14.3%) 319 (14.2%) 0.28662
Other 284 (12.6%) 302 (13.4%) 0.00682
Comorbidity history (yes)
Myocardial infarction 104 (4.6%) 113 (5.0%) 0.02865
Congestive heart failure 116 (5.2%) 125 (5.6%) 0.08273
Peripheral vascular disease 97 (4.3%) 95 (4.2%) 0.02495
Cerebrovascular disease 172 (7.6%) 172 (7.6%) 0.11255
Dementia 15 (0.7%) 8 (0.4%) 0.10249
Chronic pulmonary disease 192 (8.5%) 176 (7.8%) 0.06104
Connective tissue disease 169 (7.5%) 161 (7.1%) 0.02309
Peptic ulcer disease 129 (5.7%) 129 (5.7%) 0.07967
Mild liver disease 37 (1.6%) 30 (1.3%) 0.04168
Diabetes (type I and II) 134 (5.9%) 115 (5.1%) 0.05238
Hemiplegia 4 (0.2%) 6 (0.3%) 0.03791
Moderate to severe renal disease 55 (2.4%) 60 (2.7%) 0.06410
Diabetes with end organ damage 61 (2.7%) 47 (2.1%) 0.06301
Any tumor 260 (11.5%) 235 (10.4%) 0.09151
Leukemia 10 (0.4%) 6 (0.3%) 0.04010
Lymphoma 18 (0.8%) 14 (0.6%) 0.04218Page 6 of 12
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Metastatic solid tumor 39 (1.7%) 26 (1.2%) 0.08036
Fixation technique
Cemented 1,186 (52.6%) 1,175 (52.1%) 0.03568
Cementless 523 (23.2%) 522 (23.2%) 0.05074
Hybrid 545 (24.2%) 557 (24.7%) 0.01191
Type of anesthesia
Regional 1,753 (77.8%) 1,757 (78.0%) 0.18378
Duration of surgery (minutes)
0-60 418 (18.5%) 426 (18.9%) 0.09806
61-120 1,685 (74.8%) 1671 (74.1%) 0.03567
>121 151 (6.7%) 157 (7.0%) 0.20997
20 hospitals performing the THR procedures*
Prophylaxis for heterotopic bone formation **
Yes 195 (8.7%) 208 (9.2%) 0.06109
No 2059 (91.4%) 2046 (90.7%) 0.06268
Preoperative Hemoglobin concentration within three months prior to 
surgery
<138.5 g/L 1410 (62.6%) 1362 (60.4%) 0.25041
>138.5 g/L 844 (37.4%) 892 (39.6%) 0.25041
Year of surgery
1999 61 (2.7%) 58 (2.6% 0.03572
2000 60 (2.7%) 56 (2.5%) 0.06520
2001 94 (4.2%) 93 (4.1%) 0.02234
2002 309 (13.7%) 333 (14.8%) 0.02030
2003 239 (10.6%) 254 (11.3% 0.00876
2004 377 (16.7%) 392 (17.4%) 0.04756
2005 347 (15.4%) 333 (14.8%) 0.01024
2006 435 (19.3%) 411 (18.2%) 0.01185
2007 332 (14.7%) 324 (14.4%) 0.00976
Data are shown in number (%) unless otherwise specified. *Good balance between groups for each of the 20 hospitals included in the propensity score was 
achieved in general. ** Anti -rheumatic drugs were used as prophylaxis for heterotopic bone formation. *** A standardized mean difference that exceeds 0.1 is 
indicative of significant imbalance between groups.
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tially from the unmatched excluded patients in any of the
covariates included in the propensity score.
Table 3 shows the absolute risk of each of the outcomes in
the propensity score matched population. Figure 1 sum-
marises the crude and adjusted odds ratios for each out-
come for 2,254 transfused patients and 2,254 propensity
score matched non-transfused patients. The cumulative
90-day mortality was 1.7% among transfused patients ver-
sus 0.8% among non-transfused patients, corresponding
to an adjusted OR of 2.2 (95% CI: 1.2-3.8). For hospitali-
zation with pneumonia, there was also increased OR for
transfused patients compared with non-transfused
patients (adjusted OR 2.1, 95% CI: 1.2-3.8). Transfused
patients had non-significant increased odds of hospitali-
zation with cardiovascular and cerebrovascular events
(adjusted OR 1.4, 95% CI: 0.9-2.2) and venous throm-
boembolism (adjusted OR 1.2, 95% CI: 0.7-2.1), whereas
the odds of reoperation due to THR infection was 0.6
(95% CI: 0.1-2.9) compared with non-transfused
patients.
Patients with the most transfusions (6 or more) had the
highest odds of a composite adverse outcome (adjusted
OR 3.4, 95%CI: 1.3-9.2) compared with non-transfused
patients. However, the increased odds were not restricted
to patients receiving many transfusions, as patients receiv-
ing only 1 transfusion had increased odds of an adverse
outcome (adjusted OR 2.7, 95% CI: 1.2-5.7). Patients
who received 2-3 or 4-5 transfusions had nonsignificant
increased odds for the composite outcome of 1.2 (95%
CI: 0.8-1.9) and 1.5 (95% CI: 0.8-2.9), respectively.
Crude and adjusted odds ratios of adverse outcomes within 90 days of primary total hip replacement (THR) associated with red blood cell transfusion am ng prop nsity score matched patientFigure 1
Crude and adjusted odds ratios of adverse outcomes within 90 days of primary total hip replacement (THR) 
associated with red blood cell transfusion among propensity score matched patients. Submitted and labelled sepa-
rately. Legend: * odds ratio with 95% confidence interval. ** odds ratio adjusted for haemoglobin concentration 1-7 days post-
operative. Reference group is non-transfused patients.
Outcome OR (95% CI)*
Death
crude 2.17 (1.24−3.79)
adjusted** 2.17 (1.24−3.80)
Pneumonia
crude 2.12 (1.19−3.77)
adjusted** 2.12 (1.18−3.81)
Reoperation due to Infection of THR
crude 1.00 (0.29−3.45)
adjusted** 0.57 (0.11−2.93)
Deep venous thrombosis/pulmonary embolism
crude 1.22 (0.70−2.11)
adjusted** 1.17 (0.67−2.06)
Cardiovascular or cerebrovascular disease
crude 1.38 (0.92−2.09)
adjusted** 1.42 (0.93−2.15)
composite outcome
crude 1.64 (1.21−2.22)
adjusted** 1.67 (1.23−2.26)
l
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Using the same covariates included in the propensity
score matching (table 2), we were able to match 407 trans-
fused THR procedures to 407 unique non-transfused THR
procedures, all with a history of cardiovascular events, and
1,834 transfused THR patients to 1,834 unique non-trans-
fused THR patients, all without a history of cardiovascular
events. For THR patients with a history of cardiovascular
events prior to surgery, red blood cell transfusion was
associated with odds of the composite adverse outcome
within 90 days of surgery of 1.2 (CI: 0.8-1.9) compared
with non-transfused patients. In THR patients without
cardiovascular events prior to surgery, the odds of the
composite outcome was 1.7 (CI: 1.1-2.7) among trans-
fused versus non-transfused patients.
Using the same covariates included in the propensity
score matching (table 2), we matched 729 transfused THR
patients to 749 unique non-transfused THR patients, all
with a postoperative haemoglobin concentration below
105 g/L, and 1,505 transfused THR patients to 1,505
unique non-transfused THR patients, all with postopera-
tive haemoglobin concentration of greater than 105 g/L.
Among THR patients with postoperative haemoglobin
below 105 g/L, the adjusted OR for the composite adverse
outcome within 90 days of surgery was 1.1 (CI: 0.5-2.7)
for transfused patients compared with non-transfused
patients. In contrast, among THR patients with a postop-
erative haemoglobin level above 105 g/L, the adjusted OR
for composite outcome within 90 days of surgery was 1.6
(CI: 1.0-2.5) for transfused compared with non-trans-
fused patients.
Discussion
In this large population-based follow-up study of primary
THR patients, we found that red blood cell transfusion
was associated with substantially increased odds of an
adverse outcome, in particular death and pneumonia.
Strengths and limitations
Strengths of the present study include the large sample
size and the population-based design with complete fol-
low-up for all patients included in the study population.
All data were prospective collected independently of the
objective of our study. Since the study population was
identified only after collection of data had ended, this is a
retrospective (or historical) population-based cohort
study. The DHR database had a high validity [16]. The
quality of registration of diagnoses in the Danish National
Registry of Patients has also been established [21-24].
Nevertheless, any misclassification and errors of diagnosis
codes may bias our findings if related to transfusion. Fur-
ther, our estimates would be biased if some hospitaliza-
tions with specific outcomes were based on symptoms
arising after transfusion versus pre-transfusion. Data on
red blood cell transfusions are directly drawn from the
blood bank systems in which registration of all blood
products is mandatory according to Danish law. The
number of transfusions registered in the Danish Transfu-
sion Database is in accordance with the official statistics
on use of blood products in Denmark reported by the
Danish Medicines Agency [25].
The major methodological concern in observational stud-
ies on medical interventions, including transfusion, is the
obvious risk of bias due to confounding; this is also the
case in our study. Detailed and complete data on patient-
and procedure-related characteristics were available and
thorough efforts were made, including a combination of
propensity score matching and multivariable adjustment
techniques, to minimize any impact of confounding on
the results. Although the covariates included in the pro-
pensity score were chosen based on the current guidelines
for transfusion and literature reporting on factors affecting
the decision whether to transfuse or not, we don't know to
what degree these covariates are truly transfusion triggers
in Danish orthopaedic departments or to what extent phy-
Table 3: Number of adverse events within 90 days after primary total hip replacement (THR) among propensity score matched 
patients who were eligible for red blood cell transfusion.
Propensity score matching model
Outcome Transfusion
n = 2,254
Non-transfusion
n = 2,254
Death 39 (1.7%) 18 (0.8%)
Cardiovascular or cerebrovascular disease 54 (2.4%) 39 (1.7%)
Deep venous thrombosis and/or pulmonary embolism 28 (1.2%) 23 (1.0%)
Pneumonia 36 (1.6%) 17 (0.8%)
Reoperation due to Infection of THR 5 (0.2%) 5 (0.2%)Page 9 of 12
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on substantial differences in the use of red blood cell
transfusion among THR patients when comparing a sam-
ple of Danish orthopaedic departments, which could not
be explained by a range of patient- and surgery-related fac-
tors [26]. Further, we included patients with a preopera-
tive haemoglobin level above 105 g/L that were
transfused, which seems to deviate from current guide-
lines. However, as we don't have data on blood loss dur-
ing surgery, the surgeon may still have followed the
guidelines if these patients suffered blood loss during sur-
gery and received transfusion afterwards. Information on
pre- and postoperative haemoglobin concentration was
further included as a surrogate measure of blood loss. We
cannot exclude the possibility that residual confounding
due to the use of crude variables (e.g. the severity of
comorbidities, or pre-operative haemoglobin level above
or below 138.5 g/L only) or unknown/unmeasured prog-
nostic factors (e.g. exact volume of blood loss during the
surgery which could potentially be the actual driver of
adverse outcomes or life style factors) may have influ-
enced the results. Data on use of autologous red blood cell
transfusions and leukoreduction of transfusions were not
available.
Comparison with other studies
Our findings regarding the increased odds of death within
90 days after THR are consistent with several studies on
critically ill patients, orthopaedic trauma patients, hip
fracture patients, and patients undergoing cardiac surgery
[6-9,13,15,27]. THR patients are generally considered to
be a patient group with a low mortality compared with the
general population, and somehow, transfusion adversely
affected this relationship [28].
An association between transfusion and increased odds of
postoperative vascular complications has previously been
found among patients undergoing cardiac surgery and
among patients admitted to intensive care units [8,27,29].
A study of patients undergoing total hip or knee replace-
ment showed that fluid overload is a common complica-
tion following allogeneic blood transfusion, which agrees
with our results [11]. Nevertheless, the results are not
directly comparable since diuretic consumption was used
as a surrogate measure for fluid overload and a cardiovas-
cular event, and the study by Bierbaum and colleagues did
not take underlying comorbidities and other confounding
factors into account. Although the mechanism linking
transfusion with cardiac complications remains unclear,
several factors may contribute. These factors include aug-
mentation of the inflammatory response responsible for
the release of inflammatory mediators, or vasoconstrictors
that may facilitate plaque rupture and subsequent throm-
bosis [30]. Another likely explanation is that a patient's
underlying heart condition combined with multiple,
rapid blood transfusions lead to pulmonary oedema.
However, in our study we found increased odds of adverse
outcome for patients with and without a history of cardi-
ovascular disease, although the odds were only statistical
significant in the latter group.
Increased odds of pneumonia in transfused versus non-
transfused patients is consistent with the results of some,
but not all previous studies [11,14,31]. These inconsistent
results may be due to limited sample size, inhomogene-
ous study populations, and surgery involving different
joints. In addition, previous studies have reported on the
risk of postoperative infection in general, including pneu-
monia, wound infection, urinary infection, and bacterae-
mia, rather than the risk of pneumonia only. This makes
it difficult to directly compare the results of previous stud-
ies to one another and to our data. The mechanism under-
lying the association between transfusion and subsequent
pneumonia has not been established. However, it appears
likely that systemic immunosuppression due to transfu-
sion-associated infusion of large amounts of foreign anti-
gens changes the cellular responses of the recipient.
Nevertheless, a meta-analysis of 15 randomized control-
led trials and 40 observational studies showed no clear
link between transfusion-related immunomodulation
and risk of postoperative infection [32]. However, it was
not possible to reach a conclusion specifically on the risk
of developing pneumonia based on the meta-analysis,
since data on postoperative pneumonia were not availa-
ble in all studies. Marik and Corwin published a system-
atic review based on 45 cohort studies, suggesting that
transfusions are associated with increased morbidity and
mortality risk in high risk hospitalized patients [33]. It has
to be noted that our study is based on allogeneic transfu-
sions, and the findings may differ among patients who
received autologous red blood cell transfusions. Tradi-
tionally, allogeneic blood transfusion has been much
more prevalent in Denmark, and data on autologous
transfusions were not available for our study.
Previous publications suggest that haemoglobin is a
strong predictor for blood transfusion [34]. Nevertheless,
data on preoperative haemoglobin concentration was
only available for one third of the transfused THR patients
in our study. Furthermore, it has been shown that 75% of
total hip arthroplasty patients who received a transfusion
were not anaemic preoperatively, suggesting that other
factors play a considerable role in the decision to transfuse
[35].
We had no information on blood loss during surgery,
which may affect prognosis after transfusion and change
the quality and focus of our observations if related to
transfusion, i.e., if patients who received transfusion had
more blood loss than patients who did not receive trans-Page 10 of 12
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associated with blood loss rather than transfusion. To
address this issue we performed stratified analyses on
postoperative haemoglobin concentration as a surrogate
measure of blood loss. Our observations regarding
increased odds of adverse outcome among patients with a
high or normal postoperative haemoglobin concentration
but not among patients with a low postoperative haemo-
globin concentration confirm and extend observations
made in different settings. One previous study of coronary
surgery patients showed increased mortality and inci-
dence of myocardial infarction in transfused patients with
a haemoglobin concentration of more than 90 g/L com-
pared to non-transfused patients [36]. Hebert et al.
reported in a randomized clinical trial of critically ill
patients that liberal transfusion practice (with a threshold
for transfusion of 97 g/L and more) lead to a higher rate
of cardiac events within 30 days of admission to the inten-
sive care unit compared to restrictive transfusion practice
(i.e., transfusion given when the haemoglobin concentra-
tion fell below 70 g/L) [37].
Conclusions
Allogeneic red blood cell transfusion was associated with
an adverse prognosis following primary THR. Although
the odds ratio estimates may partly be driven by unmeas-
ured bias due to blood loss during surgery, they indicate a
need for further examination of the use of allogeneic
blood transfusion in total hip replacement patients. The
risk versus benefit of transfusion among THR patients
warrants careful assessment.
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